Trevena leverages proprietary G-protein coupled receptor (GPCR) biased ligand technology licensed from Duke University to create drugs with improved efficacy and reduced side effects. The company operates as a virtual organization with approximately 23 employees, focusing on commercial execution of OLINVYK while advancing pipeline candidates through collaboration with academic institutions and the NIH.
Cyborg Score Rationale
Trevena has achieved FDA approval for OLINVYK and operates with differentiated biased ligand technology, but faces significant headwinds including minimal revenues, extremely low market cap ($1M), and trading on OTC pink sheets. The company's ability to commercialize OLINVYK remains uncertain given market penetration challenges.
Top Insights
FDA-approved OLINVYK provides regulatory validation but sales have not materialized into meaningful revenue ($3.1M in 2022)
Company transferred certain assets to Jiangsu Nhwa Pharmaceutical in January 2026, suggesting strategic repositioning
Lean operational structure (23 employees) suggests focus on partnerships rather than internal commercialization
Biased ligand platform addresses unmet needs in pain management, migraine, and opioid addiction but requires successful clinical trial outcomes
Named Competitors
NGM Biopharmaceuticals — Discovery and development of medicines for various diseases using biologic drug candidates
Array BioPharma — Targeted small molecule oncology and inflammatory disease therapeutics
Traditional Opioid Manufacturers — Established pain management solutions
Recent Developments
(January 2026) Assignment and Release Agreement with Jiangsu Nhwa Pharmaceutical for asset transfer
(April 2025) Coverage initiated by analysts at StockNews.com on NASDAQ listing
(August 2020) FDA approval of oliceridine (OLINVYK) for acute pain management
Open the full interactive Trevena, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.